GRAILGRAL -0.02%12 PS Ratio is 16.81 as of Jun. 30, 2026, which is 75% above its 10-year median of 9.61. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, GRAIL ranks worse than 91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, GRAIL's share price is $68.375.
GRAIL's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.07. Hence, GRAIL's PS Ratio for today is 16.81.
The historical rank and industry rank for GRAIL's PS Ratio or its related term are showing as below:
GRAL'
s PS Ratio Range Over the Past 10 Years
Min: 3.45 Med: 9.61 Max: 27.18
Current: 16.77
During the past 6 years, GRAIL's highest PS Ratio was 27.18. The lowest was 3.45. And the median was 9.61.
GRAL's PS Ratio is ranked worse than 91% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.83
vs GRAL: 16.77
GRAIL's Revenue per Sharefor the
three
months ended in Mar. 2026 was $1.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.07.
During the past 12 months, the average Revenue per Share Growth Rate of GRAIL was 1.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 30.80% per year.
During the past 6 years, GRAIL's highest 3-Year average Revenue per Share Growth Rate was 30.80% per year. The lowest was 30.80% per year. And the median was 30.80% per year.
Back to Basics: PS Ratio
GRAIL (NAS:GRAL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
GRAIL PS Ratio Related Terms
GRAIL PS Ratio Historical Data
* Premium members only.
The historical data trend for GRAIL's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GRAIL's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRAIL PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's PS Ratio distribution charts can be found below:
* The bar in red indicates where GRAIL's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
GRAIL's Share Price of today is $68.375. GRAIL's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
GRAIL (GRAL) has a PS Ratio of 16.81 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GRAIL and its competitors. This is 75% above median its historical median of 9.61. Over the past decade, GRAIL's PS Ratio has ranged from 3.45 to 27.18. According to the industry distribution chart, GRAIL ranks #182 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 91%.
Is GRAIL's PS Ratio too high?
GRAIL's current PS Ratio of 16.81 is 75% above median its 10-year median of 9.61. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 27.18. The Medical Diagnostics & Research industry median PS Ratio is 2.83. GRAIL's value of 16.81 is 494% above this industry median. Based on the distribution chart, GRAIL ranks #182 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's PS Ratio compare to ADPT and WGS?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #182 out of 200 companies for PS Ratio. This places GRAIL in the lower half of its industry. The industry median PS Ratio is 2.83. GRAIL's value of 16.81 is 494% above this benchmark. Historically, GRAIL's own PS Ratio has ranged from 3.45 to 27.18 over the past decade. While the company's 10-year median is 9.61 vs. the industry median of 2.83, GRAIL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.83, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRAIL's current PS Ratio of 16.81 is 494% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current PS Ratio is 16.81, which is 75% above median its own 10-year median of 9.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current PS Ratio of 16.81. The current PS Ratio is 16.81, which is 75% above median its 10-year median of 9.61 and 494% above the Medical Diagnostics & Research industry median of 2.83. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For GRAIL (GRAL), the current PS Ratio is 16.81 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score
Get the complete analysis for GRAL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRAL has been successfully added to your 
